Results 1 to 10 of about 1,429,326 (362)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Transglutaminases and receptor tyrosine kinases [PDF]

Amino Acids, 2011
Transglutaminases are confounding enzymes which are known to play key roles in various cellular processes. In this paper, we aim to bring together several pieces of evidence from published research and literature that suggest a potentially vital role for transglutaminases in receptor tyrosine kinases (RTK) signalling.
Sivaramakrishnan, Manas, Shooter, Gary, Upton, Zee, Croll, Tristan   +3 more
openaire   +4 more sources

Pro-inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine (*)

Journal of Biological Chemistry, 1995
Protein kinases activated by dual phosphorylation on Tyr and Thr (MAP kinases) can be grouped into two major classes: ERK and JNK. The ERK group regulates multiple targets in response to growth factors via a Ras-dependent mechanism.
J. Raingeaud, Shashi Gupta, J. S. Rogers, M. Dickens, Jiahuai Han, R. Ulevitch, R. Davis   +6 more
semanticscholar   +1 more source

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study

Middle East Journal of Cancer, 2013
Background: According to numerous studies, FMS-like tyrosine kinase 3, internal tandem duplication, and the D835 mutation are associated with a poor prognostic clinical outcome in acute myeloid leukemia patients. Detection of the FMS-like tyrosine kinase
Hind Dehbi, Yaya Kassogue, Sanaa Nasserddine, Asma Quessar, Sellama Nadifi   +4 more
doaj  

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Frontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa, Ivan Alvarez-Twose   +1 more
doaj   +1 more source

Asymmetric Tyrosine Kinase Arrangements in Activation or Autophosphorylation of Receptor Tyrosine Kinases

Molecules and Cells, 2010
Receptor tyrosine kinases (RTKs) play important roles in the control of many cellular processes including cell proliferation, cell adhesion, angiogenesis, and apoptosis. Ligand-induced dimerization of RTKs leads to autophosphorylation and activation of RTKs.
Joseph Schlessinger, Jae Hyun Bae
openaire   +3 more sources

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Haematologica, 2011
Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk, Christian Lorentz, Uwe Schwindel, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus   +9 more
doaj   +1 more source

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase. [PDF]

PLoS ONE, 2015
The c-abl proto-oncogene encodes a nonreceptor tyrosine kinase that is found in all metazoans, and is ubiquitously expressed in mammalian tissues. The Abl tyrosine kinase plays important roles in the regulation of mammalian cell physiology.
Saadat U Aleem, Barbara P Craddock, W Todd Miller   +2 more
doaj   +1 more source